Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
W P MasonJ L Finlay

Abstract

To evaluate a strategy that avoids radiotherapy in children less than 6 years of age with newly diagnosed malignant brain tumors, by administering myeloablative consolidation chemotherapy with autologous bone marrow reconstitution (ABMR) after maximal surgical resection and conventional induction chemotherapy. Between March 1991 and April 1995, 62 children (median age, 30 months) with newly diagnosed malignant brain tumors were enrolled onto this trial. Children received conventional induction chemotherapy with vincristine, cisplatin, cyclophosphamide, and etoposide, repeated every 3 weeks for five cycles. Children without disease progression on induction chemotherapy were offered consolidation with myeloablative chemotherapy that incorporated carboplatin, thiotepa, and etoposide followed by ABMR. Irradiation was used only for residual tumor at consolidation or for progressive/recurrent disease. Induction chemotherapy was well tolerated by most patients; however, progression was noted in 17 children (27%) and four (6%) died of treatment complications. Of 37 children who received consolidation chemotherapy with ABMR, 15 are free of disease progression (median post-ABMR without further treatment, >44 months). The remaining 22 all...Continue Reading

Citations

Apr 1, 1999·Pediatric Hematology and Oncology·E Mantadakis, B Kamen
Nov 7, 2000·Cancer·I J DunkelD H Abramson
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger J PackerLeslie L Robison
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shakeel ModakJonathan L Finlay
Dec 22, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan N ChiJonathan L Finlay
Apr 7, 2005·Bone Marrow Transplantation·S DallorsoUNKNOWN EBMT-PDWP
Jan 31, 2006·Neuro-oncology·David S ZieglerUNKNOWN Australian and New Zealand Children's Study Group
Jun 9, 2006·Expert Review of Anticancer Therapy·Maura Massimino, Veronica Biassoni
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valerie LaroucheEric Bouffet
Oct 11, 2007·Pediatric Blood & Cancer·Kenneth J Cohen
Oct 21, 2009·Journal of Child Neurology·Stergios Zacharoulis, Lucas Moreno
Feb 11, 2010·Pediatric Blood & Cancer·Stefan RutkowskiJacques Grill
Apr 7, 2010·Expert Review of Neurotherapeutics·Dattatraya Muzumdar, Enrique C G Ventureyra
Mar 20, 2010·CNS Drugs·Laura J Klesse, Daniel C Bowers
Nov 13, 2009·Pediatric Blood & Cancer·Ira J DunkelDavid H Abramson
May 21, 2010·Pediatric Blood & Cancer·Ira J DunkelDavid H Abramson
Jun 8, 2010·Journal of Neuro-oncology·Stephen A SandsJonathan L Finlay
Aug 10, 1999·American Journal of Clinical Oncology·D R FlemingR H Herzig
Feb 24, 2001·Journal of Pediatric Hematology/oncology·A NarendranJ F Kelleher
Jul 24, 2001·Journal of Pediatric Hematology/oncology·R L Heideman
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A W WalterL E Kun
Apr 3, 2003·Current Treatment Options in Neurology·Catherine A. Mazzola, Ian F. Pollack
Jul 16, 2005·Pediatric Hematology and Oncology·Soumen Khatua, Rakesh Jalali
May 6, 2004·Pediatric Transplantation·Sharon L Gardner
Dec 3, 2003·Bone Marrow Transplantation·Y Nieto, W P Vaughan
Nov 30, 2006·Pediatric Hematology and Oncology·Jonathan L FinlayRoger J Packer
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joanne M HildenJaclyn A Biegel
Apr 12, 2007·Expert Review of Neurotherapeutics·James W ClarkeSimon S Lo
Feb 25, 2005·Neurosurgical Focus·Mandeep S Tamber, James T Rutka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.